Neuralink, founded by Elon Musk in 2016, is a neurotechnology company focused on developing implantable brain-computer interfaces (BCIs) to address neurological conditions and, eventually, augment human capabilities. Given its status as a private, pre-commercial medical device company, its financial growth is measured by its success in raising capital and establishing valuation.

• Total Capital Raised: Neuralink has raised approximately $1.3 billion in total funding since its founding.

• Series C (July 2021): The company raised $205 million in a funding round, which gave it a post-money valuation of approximately $2.15 billion.

• Series D (August 2023): Neuralink announced a funding round that secured $280 million.

• Valuation Growth (2023): Based on privately executed stock trades and investor reports, the company's valuation was estimated to be around $5 billion in late 2023.

• Series E (June 2025): The company officially closed its $650 million Series E funding round, its largest single raise to date.

• Valuation Jump (2025): The Series E round, with participation from major investors like Sequoia Capital and Founders Fund, was widely reported to have valued the company at $9 billion (pre-money valuation).

• Revenue Projection (Internal Document): The company's internal documents, reported publicly, project an aim to reach $1 billion in annual revenue by 2031, based on a projected 20,000 implants per year.

This successful fundraising highlights investor confidence in the long-term potential of BCI technology, particularly as Neuralink progresses with its human clinical trials (currently involving five patients with severe paralysis using the device).